Anzeige
Erschienen in:
01.05.2015 | Research Commentary
Letter regarding Li JS et al. entitled “ERCC polymorphisms and prognosis of patients with osteosarcoma”
Erschienen in: Tumor Biology | Ausgabe 5/2015
Einloggen, um Zugang zu erhaltenAbstract
With great interest, we read the article “ERCC polymorphisms and prognosis of patients with osteosarcoma” (by Li JS et al.), which has reached important conclusions about the relationship between ERCC polymorphisms and osteosarcoma prognosis. Through quantitative analysis, the meta-analysis showed that ERCC2 Lys751Gln (ORGG vs. AA = 0.40 (95%CI = 0.1–0.86), P
heterogeneity = 0.502; I
2 = 0 %) and ERCC5 His46His (ORCC vs. TT = 0.37 (95%CI = 0.15–0.93), P
heterogeneity = 0.569; I
2 = 0 %) polymorphisms might influence the prognosis of patients with osteosarcoma [1]. The meta-analysis results are encouraging. Nevertheless, some deficiencies still existed that we would like to raise.